Drug Trial Radar · NCT00245921
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
Last checked: Nov 20, 2026Latest source record: Feb 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Feb 2003
Primary completion
Oct 2005
Study completion Oct 2005
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 28, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.
Conditions
- Contraception
Interventions
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate safety and contraceptive efficacy
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.